July 2025 – Tokyo, Japan & Ann Arbor, MI , Tokyo-based nuclear medicine startup AMS, U.S.-based medical device company M3D, Inc., and Japanese infrastructure and engineering firm Tokyo Power Technology Ltd. (TPT), a wholly owned subsidiary of Tokyo Electric Power Company Holdings, have announced a strategic partnership to deliver a radiation safety solution that enables Japanese hospitals to increase patient throughput while adopting radiopharmaceutical therapies.

Under the terms of the agreement, AMS will serve as the exclusive subcontractor to TPT, which will act as the sole distributor of M3D products in Japan. The collaboration integrates AMS and TPT’s co-developed BSL-177, a shielding and containment system for radiopharmaceutical waste, with M3D’s RAVIN CAM, a compact and precise radiation measurement device developed in Michigan. Together, these technologies help hospitals safely assess residual radiation and manage shielding at the bedside, enabling faster patient discharge and improved workflow efficiency.

With the increasing adoption of new radiopharmaceutical therapies, hospitals in Japan are facing growing pressure to optimize treatment capacity while maintaining strict safety and regulatory standards. The combined solution directly addresses these operational challenges, helping institutions reduce discharge delays and treat more patients without expanding infrastructure.

“By integrating BSL-177 and RAVIN CAM, we’re offering a highly practical solution tailored for the needs of Japanese hospitals adopting radiopharmaceutical therapies,” said Yuichiro Sugawara, Founder and CEO of AMS. “It also marks a strategic collaboration between a University of Michigan–backed startup and a Hokkaido University–originated venture, with strong backing from a well-established Japanese enterprise.”

“This partnership represents a powerful combination of U.S. medical device innovation and Japan’s clinical and infrastructure expertise,” said Michael Hopkins, CEO of M3D. “By aligning with TPT and AMS, we are positioned to help Japanese hospitals safely manage the growing adoption of radiopharmaceutical treatments.”

For more information: